Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

123.04 

2.22 1.8%

as of Jul 15 '19

52 Week Range:

92.56 141.82


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 1.58
3.87
4.70
5.69
10.12
11.96
15.69
36.57
37.96
40.23
41.03
growth rate 144.9% 21.5% 21.1% 77.9% 18.2% 31.2% 133.1% 3.8% 6.0% 2.0%
Earnings BIT 34.73
83.31
149.01
229.67
397.57
526.27
916.00
682.20
793.40
983.30
1,619.90
growth rate 139.9% 78.9% 54.1% 73.1% 32.4% 74.1% -25.5% 16.3% 23.9% 64.7%
Avg.PE 98.04
14.99
77.52
78.13
72.99
105.26
55.92
210.61
74.74
50.98
345.23
growth rate -84.7% 417.1% 0.8% -6.6% 44.2% -46.9% 276.6% -64.5% -31.8% 577.2%
ROA 8.17
46.71
10.79
14.57
12.71
8.53
17.47
1.67
3.02
3.30
0.56
growth rate 471.7% -76.9% 35.0% -12.8% -32.9% 104.8% -90.4% 80.8% 9.3% -83.0%
ROE 19.02
63.11
12.54
17.58
16.41
11.62
23.11
2.50
4.71
5.04
0.86
growth rate 231.8% -80.1% 40.2% -6.7% -29.2% 98.9% -89.2% 88.4% 7.0% -82.9%
ROIC 10.31
54.21
12.34
17.44
15.94
11.05
22.52
2.10
3.97
4.44
0.92
growth rate 425.8% -77.2% 41.3% -8.6% -30.7% 103.8% -90.7% 89.1% 11.8% -79.3%
Cur. Ratio 3.28
4.38
4.67
4.09
4.15
3.75
4.61
3.38
3.13
3.10
2.88
growth rate 33.5% 6.6% -12.4% 1.5% -9.6% 22.9% -26.7% -7.4% -1.0% -7.1%
Quick Ratio 2.52
3.40
3.83
3.41
3.57
3.33
3.95
2.67
2.36
2.31
2.12
growth rate 34.9% 12.7% -11.0% 4.7% -6.7% 18.6% -32.4% -11.6% -2.1% -8.2%
Leverage 1.93
1.14
1.18
1.23
1.33
1.39
1.27
1.59
1.52
1.53
1.52
growth rate -40.9% 3.5% 4.2% 8.1% 4.5% -8.6% 25.2% -4.4% 0.7% -0.7%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 74.50
113.70
168.70
263.42
321.68
463.18
432.89
533.00
649.60
726.50
922.30
growth rate 52.6% 48.4% 56.2% 22.1% 44.0% -6.5% 23.1% 21.9% 11.8% 27.0%
Acct.Payable 199.65
271.28
423.94
44.02
57.00
64.10
70.80
74.40
growth rate 35.9% 56.3% -89.6% 29.5% 12.5% 10.5% 5.1%
Cur.Assets 277.10
373.50
646.60
941.27
1,495.60
2,186.86
2,796.03
2,416.00
2,578.20
2,953.90
3,385.00
growth rate 34.8% 73.1% 45.6% 58.9% 46.2% 27.9% -13.6% 6.7% 14.6% 14.6%
Total Assets 477.60
786.40
1,012.00
1,394.75
2,613.56
3,317.70
4,201.96
13,097.00
13,253.30
13,583.30
13,931.90
growth rate 64.7% 28.7% 37.8% 87.4% 26.9% 26.7% 211.7% 1.2% 2.5% 2.6%
Cash 138.00
157.20
267.10
540.87
989.50
529.86
944.00
1,010.00
966.00
584.40
1,365.50
growth rate 13.9% 69.9% 102.5% 83.0% -46.5% 78.2% 7.0% -4.4% -39.5% 133.7%
Inventory 49.80
40.90
62.20
81.39
94.52
102.60
176.44
290.00
374.70
460.40
472.50
growth rate -17.9% 52.1% 30.9% 16.1% 8.6% 72.0% 64.4% 29.2% 22.9% 2.6%
Cur.Liabilities 84.40
85.30
138.50
227.79
360.09
582.43
606.74
709.00
822.90
952.50
1,174.00
growth rate 1.1% 62.4% 64.5% 58.1% 61.8% 4.2% 16.9% 16.1% 15.8% 23.3%
Liabilities 230.60
98.00
152.30
260.26
642.71
935.62
899.94
4,838.00
4,559.50
4,690.20
4,766.60
growth rate -57.5% 55.4% 70.9% 147.0% 45.6% -3.8% 437.6% -5.8% 2.9% 1.6%
LT Debt 141.40
10.40
4.50
0.00
101.00
97.23
9.50
3,254.00
2,888.10
2,720.70
2,519.00
growth rate -92.6% -56.7% -100.0% -3.7% -90.2% 34,152.6% -11.2% -5.8% -7.4%
Equity 247.00
688.40
859.70
1,134.49
1,970.85
2,382.08
3,302.02
8,259.00
8,693.80
8,893.10
9,165.30
growth rate 178.7% 24.9% 32.0% 73.7% 20.9% 38.6% 150.1% 5.3% 2.3% 3.1%
Common Shares 180.00
181.00
186.00
192.00
199.00
200.00
202.00
216.00
226.00
225.00
225.00
growth rate 0.6% 2.8% 3.2% 3.7% 0.5% 1.0% 6.9% 4.6% -0.4% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 39.70
35.30
12.80
21.98
21.85
29.33
137.00
286.30
332.70
357.30
213.00
growth rate -11.1% -63.7% 71.7% -0.6% 34.3% 367.1% 109.0% 16.2% 7.4% -40.4%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 53.20
113.80
160.90
270.08
410.61
497.35
640.00
675.20
1,086.30
1,115.60
426.00
growth rate 113.9% 41.4% 67.9% 52.0% 21.1% 28.7% 5.5% 60.9% 2.7% -61.8%
FCF per Share 0.03
0.28
0.80
1.11
1.96
1.83
2.34
2.43
2.37
3.81
1.52
growth rate 833.3% 185.7% 38.8% 76.6% -6.6% 27.9% 3.9% -2.5% 60.8% -60.1%
Sale Purchase of Stock 35.77
517.10
5.15
114.00
82.00
37.10
85.90
growth rate 1,345.8% -99.0% 2,115.7% -28.1% -54.8% 131.5%
FCF 5.00
51.00
148.00
248.00
389.00
468.00
503.00
389.00
753.00
758.00
213.00
growth rate 920.0% 190.2% 67.6% 56.9% 20.3% 7.5% -22.7% 93.6% 0.7% -71.9%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 259.10
386.80
541.00
783.43
1,134.11
1,551.35
2,234.00
2,604.00
3,084.10
3,551.10
4,131.20
growth rate 49.3% 39.9% 44.8% 44.8% 36.8% 44.0% 16.6% 18.4% 15.1% 16.3%
Op.Income 34.60
87.10
150.60
175.32
254.82
252.90
916.00
682.20
793.40
983.30
1,619.90
growth rate 151.7% 72.9% 16.4% 45.4% -0.8% 262.2% -25.5% 16.3% 23.9% 64.7%
IBT 34.70
83.30
149.00
229.67
397.57
526.27
872.00
498.10
576.20
547.80
242.20
growth rate 140.1% 78.9% 54.1% 73.1% 32.4% 65.7% -42.9% 15.7% -4.9% -55.8%
Net Income 33.10
295.20
97.00
175.32
254.82
252.90
657.00
144.40
399.40
443.30
77.60
growth rate 791.8% -67.1% 80.7% 45.4% -0.8% 159.8% -78.0% 176.6% 11.0% -82.5%
EPS 0.20
1.63
0.52
0.91
1.28
1.27
3.26
0.67
1.76
1.97
0.35
growth rate 715.0% -68.1% 75.0% 40.7% -0.8% 156.7% -79.5% 162.7% 11.9% -82.2%
Gross Profit 230.70
341.70
476.50
690.29
1,061.28
1,373.79
2,060.00
2,370.90
2,825.80
3,249.00
3,762.70
growth rate 48.1% 39.5% 44.9% 53.7% 29.5% 50.0% 15.1% 19.2% 15.0% 15.8%
R&D 62.60
81.90
98.40
137.42
222.73
317.09
514.00
709.50
757.20
862.10
730.30
growth rate 30.8% 20.2% 39.7% 62.1% 42.4% 62.1% 38.0% 6.7% 13.9% -15.3%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 334.60
425.90
430.30
429.10
497.20
growth rate 27.3% 1.0% -0.3% 15.9%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 776.70
853.70
910.20
922.30
1,016.30
growth rate 9.9% 6.6% 1.3% 10.2%
Acct.Payable 57.10
58.80
52.20
74.40
659.00
growth rate 3.0% -11.2% 42.5% 785.8%
Cur.Assets 3,152.00
2,836.10
3,248.40
3,385.00
3,650.60
growth rate -10.0% 14.5% 4.2% 7.9%
Total Assets 13,830.20
13,490.40
13,843.60
13,931.90
13,999.60
growth rate -2.5% 2.6% 0.6% 0.5%
Cash 511.80
727.50
1,228.90
1,365.50
1,544.80
growth rate 42.2% 68.9% 11.1% 13.1%
Inventory 456.50
463.20
432.70
472.50
482.20
growth rate 1.5% -6.6% 9.2% 2.1%
Cur.Liabilities 942.00
1,044.40
1,027.40
1,174.00
943.80
growth rate 10.9% -1.6% 14.3% -19.6%
Liabilities 4,717.50
4,723.00
4,673.90
4,766.60
4,293.00
growth rate 0.1% -1.0% 2.0% -9.9%
LT Debt 2,678.80
2,564.90
2,533.30
2,519.00
2,651.90
growth rate -4.3% -1.2% -0.6% 5.3%
Equity 9,112.70
8,767.40
9,169.70
9,165.30
9,706.60
growth rate -3.8% 4.6% -0.1% 5.9%
Common Shares 9,165.30
9,706.60
growth rate 5.9%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 66.60
62.80
41.20
42.40
36.00
growth rate -5.7% -34.4% 2.9% -15.1%
Cash Dividends
growth rate
Cash From OA 299.30
-343.80
387.10
83.40
429.90
growth rate -100.0% 100.0% -78.5% 415.5%
Sale Purchase of Stock 9.40
15.20
growth rate 61.7%
FCF 232.70
-406.60
345.90
41.00
393.90
growth rate -100.0% 100.0% -88.2% 860.7%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 930.90
1,045.00
1,026.50
1,128.80
1,140.40
growth rate 12.3% -1.8% 10.0% 1.0%
Op.Income 334.60
425.90
430.30
429.10
497.20
growth rate 27.3% 1.0% -0.3% 15.9%
IBT 351.60
-418.60
342.10
-32.90
541.80
growth rate -100.0% 100.0% -100.0% 100.0%
Net Income 249.10
-457.40
330.90
-45.00
587.90
growth rate -100.0% 100.0% -100.0% 100.0%
EPS
growth rate
Gross Profit 844.60
950.20
935.90
1,032.00
1,054.60
growth rate 12.5% -1.5% 10.3% 2.2%
R&D 176.50
173.40
174.80
205.60
195.90
growth rate -1.8% 0.8% 17.6% -4.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (18.99)

YOY Growth Grade:

C (60.98)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 73.41 66.08 12.74
EPS / Growth 14.6% 1.86 17.6%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 24.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 14.6% 18.9% 18.9%
Future PE 12.74 41.30 41.30
Future EPS 7.26 10.49 10.49
Value Price
MOS %
22.87
-81.4%
107.06
-13.0%
107.06
-13.0%
MOS Price 11.43 53.53 53.53
IRT 16.45 14.11 14.11

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.